Posted by Michael Wonder on 10 Nov 2020
Mirum Pharmaceuticals broadens Expanded Access Program for maralixibat in Alagille syndrome to Europe and Australia
5 November 2020 - Maralixibat Expanded Access Program now available for patients with pruritus associated with Alagille syndrome in Australia and 10 countries in Europe.
Mirum Pharmaceuticals today announced it has broadened its Expanded Access Program for maralixibat for the treatment of patients with cholestatic pruritus associated with Alagille syndrome to Australia and countries in Europe.
The announcement follows the Company’s recent initiation of an Expanded Access Program in the United States and Canada for maralixibat in the same indication.
